Related Experiment Videos
Novel nonsteroidal anti-inflammatory drugs.
1Service de Rhumatologie, Cliniques de l'Université Catholique de Louvain (UCL) à Mont-Godinne, Yvoir.
Acta Gastro-Enterologica Belgica
|February 29, 2000
Summary
Selective COX-2 inhibitors like celecoxib offer improved gastrointestinal safety and maintain platelet function for conditions such as osteoarthritis. Further research is needed for other inflammatory conditions and potential renal side-effects.
Area of Science:
- Pharmacology
- Gastroenterology
- Rheumatology
Background:
- Nonsteroidal anti-inflammatory drugs (NSAIDs) carry risks of gastrointestinal toxicity.
- Cyclooxygenase-2 (COX-2) selective inhibitors were developed to mitigate these risks.
- Celecoxib is a marketed COX-2 selective agent, with rofecoxib nearing release.
Purpose of the Study:
- To review the development of COX-2 selectivity.
- To assess the gastrointestinal safety, efficacy, and side effects of COX-2 selective agents.
- To explore emerging questions regarding COX-2 inhibition.
Main Methods:
- Review of existing literature on NSAIDs and COX-2 inhibitors.
- Analysis of clinical data regarding gastrointestinal safety, platelet function, and efficacy.
- Discussion of potential side effects and areas for future research.
Main Results:
- Celecoxib demonstrates high gastrointestinal safety and preserves platelet function.
- Efficacy of celecoxib is satisfactory for osteoarthritis and rheumatoid arthritis.
- Potential renal side-effects warrant caution; efficacy in acute inflammatory crises is unassessed.
Conclusions:
- Selective COX-2 inhibition offers significant gastrointestinal benefits compared to traditional NSAIDs.
- Further clinical experience and research are necessary to fully understand the long-term effects and applications of COX-2 inhibitors, including potential COX-1 activity and COX-2's role in organ homeostasis.